8-K Announcements
6Material company update
Apr 24, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Dec 30, 2025·SEC
Medicus Pharma Ltd. Common Stock(MDCX)Earnings, Financials & Key Ratios
MDCX•NASDAQ
Price updated Jun 19, 2026
AboutMedicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.Show more
- Revenue$0
- EBITDA-$18M-64.5%
- Net Income-$25M-127.4%
- EPS (Diluted)-1.96-69.0%
- ROE-1599.39%-204.4%
MDCX Key Insights
Medicus Pharma Ltd. Common Stock (MDCX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗High debt to equity ratio of 107.1x
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 79.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 211.9x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MDCX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MDCX Price & Volume
Medicus Pharma Ltd. Common Stock (MDCX) stock price & volume — 10-year historical chart
Loading chart...
MDCX Growth Metrics
Medicus Pharma Ltd. Common Stock (MDCX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-155.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-48.65%
Return on Capital
10 Years-662.46%
5 Years-662.46%
3 Years-662.46%
Last Year-1059.55%
MDCX Peer Comparison
Medicus Pharma Ltd. Common Stock (MDCX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SIGA | 309.85M | 4.32 | 13.09 | -31.8% | 21.61% | 10.62% | 0.00 | |
 NUVB | 1.93B | 5.56 | -9.27 | 6.99% | -102.06% | -44.1% | 0.03 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 DERM | 171.19M | 6.22 | -13.23 | 10.2% | -14.82% | -35.57% | 0.00 | |
 NTRB | 35.86M | 2.95 | -1.14 | -4.83% | -448.39% | -112.6% | 0.03 | |
 SKIN | 85.9M | 0.66 | -4.14 | -10.02% | -2.03% | -9.41% | 6.20 | |
 IQV | 28.47B | 167.77 | 21.40 | 5.87% | 8.33% | 22.11% | 2.44 |
Compare MDCX vs Peers
Medicus Pharma Ltd. Common Stock (MDCX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDCX Income Statement
Medicus Pharma Ltd. Common Stock (MDCX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - |
Operating Expenses | 1.44M | 978.42K | 4.73M | 11.18M | 18.35M | 35.5M |
OpEx % of Revenue | - | - | - | - | - | - |
Selling, General & Admin | 258.01K | 332.03K | 2.46M | 7.65M | 17.92M | 20.69M |
SG&A % of Revenue | - | - | - | - | - | - |
Research & Development | 1.18M | 646.38K | 193.58K | 3.53M | 7.72M | 17.14M |
R&D % of Revenue | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 2.07M | 0 | -7.29M | -1000K |
Operating Income | -1.44M▲ 0% | -978.42K▲ 32.1% | -4.73M▼ 383.4% | -11.18M▼ 136.4% | -18.35M▼ 64.1% | -35.5M▲ 0% |
Operating Margin % | - | - | - | - | - | - |
Operating Income Growth % | - | 32.12% | -383.43% | -136.39% | -64.13% | - |
EBITDA | -1.94M | -1.17M | -2.66M | -11.16M | -18.35M | -35.5M |
EBITDA Margin % | - | - | - | - | - | - |
EBITDA Growth % | - | 39.92% | -128.08% | -319.64% | -64.5% | -161.49% |
D&A (Non-Cash Add-back) | 0 | 0 | 2.07M | 0 | 0 | 0 |
EBIT | -1.94M | -1.17M | -2.66M | -11.16M | -18.35M | -35.5M |
Net Interest Income | -690.85K | -1.1M | -584.82K | -213.13K | -141.26K | 230.63K |
Interest Income | -575.45K | -575.45K | 10.72K | 104.41K | 0 | 51.58K |
Interest Expense | 115.41K | 526.83K | 595.54K | 317.54K | 141.26K | -179.05K |
Other Income/Expense | -613.88K | -713.97K | -584.82K | 25.39K | -7.02M | -1.43M |
Pretax Income | -2.06M▲ 0% | -1.69M▲ 17.7% | -5.31M▼ 214.0% | -11.16M▼ 109.9% | -25.37M▼ 127.4% | -36.93M▲ 0% |
Pretax Margin % | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -2.06M▲ 0% | -1.69M▲ 17.7% | -5.31M▼ 214.0% | -11.16M▼ 109.9% | -25.37M▼ 127.4% | -36.93M▲ 0% |
Net Margin % | - | - | - | - | - | - |
Net Income Growth % | - | 17.66% | -214.04% | -109.9% | -127.39% | -155.31% |
Net Income (Continuing) | -2.06M | -1.69M | -5.31M | -11.16M | -25.37M | -36.93M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 104.86K | 101.84K |
EPS (Diluted) | -0.26▲ 0% | -0.21▲ 19.2% | -1.06▼ 404.8% | -1.16▼ 9.4% | -1.96▼ 69.0% | -1.25▲ 0% |
EPS Growth % | - | 19.23% | -404.76% | -9.43% | -68.97% | -48.65% |
EPS (Basic) | -0.26 | -0.88 | -1.53 | -1.16 | -1.96 | - |
Diluted Shares Outstanding | 8.05M | 8.05M | 5.03M | 9.62M | 17.28M | 29.54M |
Basic Shares Outstanding | 8.05M | 1.93M | 3.48M | 9.62M | 17.28M | 29.54M |
Dividend Payout Ratio | - | - | - | - | - | - |
MDCX Balance Sheet
Medicus Pharma Ltd. Common Stock (MDCX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 78.51K | 282.65K | 1.89M | 5.38M | 9.89M | 7.28M |
Cash & Short-Term Investments | 78.51K | 267.65K | 1.72M | 4.16M | 8.71M | 6.37M |
Cash Only | 78.51K | 267.65K | 1.72M | 4.16M | 8.71M | 6.37M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 1.19M | 916.96K |
Total Non-Current Assets | 0 | 0 | 0 | 268.57K | 170.73K | 144.33K |
Property, Plant & Equipment | 0 | 0 | 0 | 268.57K | 170.73K | 144.33K |
Fixed Asset Turnover | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 78.51K▲ 0% | 282.65K▲ 260.0% | 1.89M▲ 569.7% | 5.65M▲ 198.3% | 10.06M▲ 78.2% | 7.43M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.00x |
Asset Growth % | - | 260% | 569.75% | 198.29% | 78.18% | 171.57% |
Total Current Liabilities | 10.58M | 12.48M | 781.61K | 2.31M | 9.94M | 5.95M |
Accounts Payable | 0 | 0 | 210.84K | 1.28M | 3.44M | 2.28M |
Days Payables Outstanding | - | - | - | - | - | - |
Short-Term Debt | 667.93K | 1.53M | 0 | 116.32K | 3.93M | 145.46K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9.92M | 10.95M | 27.77K | 140.99K | 2.57M | 3.53M |
Current Ratio | 0.01x | 0.02x | 2.42x | 2.33x | 1.00x | 1.22x |
Quick Ratio | 0.01x | 0.02x | 2.42x | 2.33x | 1.00x | 1.22x |
Cash Conversion Cycle | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 205.94K | 62.74K | 45.21K |
Long-Term Debt | 0 | 0 | 0 | 0 | 18.87K | 24.17K |
Capital Lease Obligations | 0 | 0 | 0 | 205.82K | 43.87K | 185.63K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 21.04K |
Total Liabilities | 10.58M | 12.48M | 781.61K | 2.51M | 10.02M | 6M |
Total Debt | 667.93K | 1.53M | 0 | 322.27K | 4M | 169.62K |
Net Debt | 589.42K | 1.26M | -1.72M | -3.84M | -4.71M | -6.2M |
Debt / Equity | - | - | - | 0.10x | 107.09x | 0.12x |
Debt / EBITDA | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | 0.17x |
Interest Coverage | -16.81x | -2.21x | -4.46x | -35.13x | -129.91x | 198.27x |
Total Equity | -10.51M▲ 0% | -12.2M▼ 16.1% | 1.11M▲ 109.1% | 3.13M▲ 182.0% | 37.31K▼ 98.8% | 1.43M▲ 0% |
Equity Growth % | - | -16.11% | 109.11% | 182.04% | -98.81% | -305.33% |
Book Value per Share | -1.31 | -1.52 | 0.22 | 0.33 | 0.00 | 0.05 |
Total Shareholders' Equity | -10.51M | -12.2M | 1.11M | 3.13M | -67.55K | 1.33M |
Common Stock | 194.54K | 194.54K | 18.76M | 30.52M | 57.08M | 67.11M |
Retained Earnings | -10.7M | -12.39M | -17.75M | -28.9M | -64.35M | -73.39M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 10.88K | -190.51K |
Minority Interest | 0 | 0 | 0 | 0 | 104.86K | 101.84K |
MDCX Cash Flow Statement
Medicus Pharma Ltd. Common Stock (MDCX) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | -1.45M | -1.06M | -4.16M | -10.25M | -22.78M | -23.41M |
Operating CF Margin % | - | - | - | - | - | - |
Operating CF Growth % | - | 27% | -293.36% | -146.43% | -122.27% | -338.69% |
Net Income | -2.06M | -1.69M | -5.31M | -11.16M | -35.44M | -36.93M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 0 | 0 | 98.58K | 713.12K | 1.51M | 117.45K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 613.88K | 713.97K | 584.82K | 162.24K | 10.75M | 12.5M |
Working Capital Changes | -6.66K | -78.69K | 473.1K | 32.93K | 407.7K | -1.4M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 79.09K | 808.75K | 0 | -250.96K |
Cash from Investing | 0 | 0 | 0 | 0 | -4.62M | -4.65M |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | -4.62M | 0 |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | -4.65M |
Cash from Financing | 882.38K | 1.25M | 5.61M | 12.69M | 31.94M | 31.16M |
Debt Issued (Net) | 882.38K | 1.25M | 500K | 5.17M | 3.1M | 2.55M |
Equity Issued (Net) | 0 | 0 | 0 | 7.52M | 19.75M | 27.68M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 5.11M | 0 | 9.08M | 926.68K |
Net Change in Cash | -565.66K▲ 0% | 189.14K▲ 133.4% | 1.45M▲ 667.5% | 2.44M▲ 68.4% | 4.54M▲ 85.7% | 3.02M▲ 0% |
Free Cash Flow | -1.45M▲ 0% | -1.06M▲ 27.0% | -4.16M▼ 293.4% | -10.25M▼ 146.4% | -22.78M▼ 122.3% | -23.41M▲ 0% |
FCF Margin % | - | - | - | - | - | - |
FCF Growth % | - | 27% | -293.36% | -146.43% | -122.27% | -83.01% |
FCF per Share | -0.18 | -0.13 | -0.83 | -1.07 | -1.32 | -0.79 |
FCF Conversion (FCF/Net Income) | 0.70x | 0.62x | 0.78x | 0.92x | 0.90x | 0.63x |
Interest Paid | 0 | 0 | 0 | 40.56K | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
MDCX Key Ratios
Medicus Pharma Ltd. Common Stock (MDCX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
Return on Equity (ROE) | - | -478.18% | -525.44% | -1599.39% | -3789.11% |
Return on Invested Capital (ROIC) | - | - | - | - | 598.95% |
Debt / Equity | - | - | 0.10x | 107.09x | 0.12x |
Interest Coverage | -2.21x | -4.46x | -35.13x | -129.91x | 198.27x |
FCF Conversion | 0.62x | 0.78x | 0.92x | 0.90x | 0.63x |
Related:MDCX Dividend History·MDCX Revenue History·MDCX Price History·MDCX P/E History·MDCX Financial Ratios·MDCX Institutional Holders
MDCX SEC Filings & Documents
Medicus Pharma Ltd. Common Stock (MDCX) SEC filings — annual & quarterly reports (10-K, 10-Q)
MDCX Frequently Asked Questions
Medicus Pharma Ltd. Common Stock (MDCX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Medicus Pharma Ltd. Common Stock (MDCX) grew revenue by 0.0% over the past year. Growth has been modest.
Medicus Pharma Ltd. Common Stock (MDCX) reported a net loss of $36.9M for fiscal year 2025.
Dividend & Returns
Medicus Pharma Ltd. Common Stock (MDCX) has a return on equity (ROE) of -1599.4%. Negative ROE indicates the company is unprofitable.
Medicus Pharma Ltd. Common Stock (MDCX) had negative free cash flow of $23.4M in fiscal year 2025, likely due to heavy capital investments.